Population
1 44-year-old female with pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymph tissue
Design
Case_report
Follow-up
3 years
Authors
Loading...
Supports multimodal therapy for rare pulmonary MALT lymphoma; leaves open need for prospective studies to guide practice.
Pulmonary lobectomy followed by rituximab plus CHOP chemotherapy resulted in a 3-year recurrence-free survival in a patient with rare pulmonary MALT lymphoma.
Chai et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: